Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Chembio, CombiMatrix

Premium

Chembio this week named Michael Steele vice president of sales, marketing, and business development.

Steele was previously employed by Chembio as a consultant. Before that he was vice president of business development at Seracare Life Sciences as well as director and managing director at Serologicals before it was acquired by Millipore.


CombiMatrix has named Mark McDonough its new chief commercial officer.

McDonough was previously vice president of sales, customer service, and training at Pathwork Diagnostics and he spent six years at USLabs/Dianon, where he eventually became vice president of sales.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.